Colorectal Cancer Trial, Recruiting NCT03349762 Sponsor: Xi Shan Wang Condition: Colorectal Cancer
Back to Colorectal Cancer

Colorectal Cancer Trial, Recruiting

NCT03349762
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 18 and 75 years old (male or female)
  • People who have had surgery to remove colorectal cancer for the first time, within the last two months, where lab results after surgery confirmed the cancer was at stage IIB, IIC, or III
  • People with a general health and activity level rated as 0, 1, or 2 on a standard medical scale (meaning able to care for oneself, with varying levels of activity limitation) (confirm with trial site)
  • People with no history of any other cancer
  • People who are willing to participate, sign a consent form, and work with the research team to provide information

Who may not be able to join:

  • People who have existing heart conditions, stroke-related conditions, lung disease, severe high blood pressure, or diabetes that is not well controlled
  • People who have a confirmed infection following their surgery
  • People who have experienced complications from their colorectal cancer surgery, or who are still recovering from the effects of the surgery
  • People who have syphilis or other infections that can be spread through blood
  • People who are pregnant or breastfeeding, or women who could become pregnant and are not using contraception
  • People who are already taking certain traditional Chinese medicines with similar effects to the study medicine, including compound Banmao capsule, Huachansu capsule, Kangai Injection, or Pingxiao tablets
  • People with a mental illness, or any other condition the research team considers makes participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xishan Wang, Professor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phone: +0086-13552367779

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Xi Shan Wang
Registry
ClinicalTrials.gov
Start date
2 November 2018
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Disease-Free Survival(DFS); Overall survival(OS); Local recurrence-Free Survival rate; Distant Metastasis-Free Survival rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov